Spyre Therapeutics, Inc. 8-K

What Happened Spyre Therapeutics, Inc. (SYRE) filed a Form 8-K on May 5, 2026 (Item 2.02) reporting that it issued a press release announcing its financial results for the quarter ended March 31, 2026. The press release is furnished as Exhibit 99.1 to the 8-K. The report was signed by Scott Burrows, Chief Financial Officer.

Key Details

• Filing date: May 5, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Period covered: Quarter ended March 31, 2026 (Q1 2026 quarterly results).
• Disclosure furnished: Press release announcing the Q1 2026 results included as Exhibit 99.1.
• Signature: Report signed by CFO Scott Burrows; interactive XBRL cover page (Exhibit 104) also included.

Why It Matters This 8-K signals that Spyre has released its quarterly earnings and related financial information — key data investors use to evaluate revenue, earnings, cash position, and progress on corporate goals. The 8-K itself does not reproduce the financial details; investors should review the Exhibit 99.1 press release (and any accompanying SEC filings or investor presentations) for specific figures such as revenue, net loss/profit, R&D spend, cash runway, or guidance. Tracking these quarterly results helps investors assess company performance and update valuation or investment decisions.